Abstract
Almost fifteen years ago, the first non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI) lead compounds have been discovered. Nowadays, three NNRTIs are approved for treatment of HIV-1-infected individuals and several others are subject of (advanced) clinical trials. Although the NNRTIs target HIV-1 RT, they are clearly different from the nucleoside RT inhibitors (NRTIs). They are highly selective for HIV-1 and do not inhibit HIV-2 or any other (retro)virus. They target HIV-1 RT by a direct interaction without the need to be metabolised by cellular enzymes, and they interact at a site on the HIV-1 RT that is near to, but distant from, the substrate-binding site. The majority of NNRTIs share common conformational properties and structural features that let them fit in a hydrophobic pocket at the HIV-1 RT, which is nowadays well-characterized. A wide variety of crystal structures of RT complexed with NNRTIs have been obtained. They provide detailed insights in the molecular interaction of the NNRTIs with the amino acids lining the pocket in HIV-1 RT. Due to their unprecedented specificity, the NNRTIs are relatively non-toxic in cell culture, and the most potent compounds reach selectivity indices that exceed 100,000 or more. However, inherent to their high specificity, the NNRTIs easily select for mutant virus strains with several degrees of drug resistance. The first-generation NNRTIs such as nevirapine and delavirdine easily loose their inhibitory potential against mutant virus strains that contain single amino acid mutations in their RT. The second-generation NNRTIs such as efavirenz, capravirine and dapivirine usually require two or more mutations in the HIV-1 RT before significantly decreasing their antiviral potency. Evidently, it requires a markedly longer time period to obtain significant resistance against second-generation NNRTIs. The resistance spectrum of NNRTIs is entirely different from the NRTI resistance spectrum, and, as a rule, NRTI-resistant mutant virus strains keep full sensitivity to the inhibitory effects of NNRTIs, and vice versa NNRTI-resistant and mutant virus strains keep full sensitivity to the inhibitory effects of NRTIs. NNRTIs have proven beneficial when included in drug combination (triple or quadruple) therapy, preferably in the presence of protease inhibitors and NRTIs.
Keywords: non-nucleoside, reverse transcriptase inhibitors, nucleoside rt inhibitors, nevirapine, delavirdine, efavirenz
Current Topics in Medicinal Chemistry
Title: Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Volume: 4 Issue: 9
Author(s): J. Balzarini
Affiliation:
Keywords: non-nucleoside, reverse transcriptase inhibitors, nucleoside rt inhibitors, nevirapine, delavirdine, efavirenz
Abstract: Almost fifteen years ago, the first non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI) lead compounds have been discovered. Nowadays, three NNRTIs are approved for treatment of HIV-1-infected individuals and several others are subject of (advanced) clinical trials. Although the NNRTIs target HIV-1 RT, they are clearly different from the nucleoside RT inhibitors (NRTIs). They are highly selective for HIV-1 and do not inhibit HIV-2 or any other (retro)virus. They target HIV-1 RT by a direct interaction without the need to be metabolised by cellular enzymes, and they interact at a site on the HIV-1 RT that is near to, but distant from, the substrate-binding site. The majority of NNRTIs share common conformational properties and structural features that let them fit in a hydrophobic pocket at the HIV-1 RT, which is nowadays well-characterized. A wide variety of crystal structures of RT complexed with NNRTIs have been obtained. They provide detailed insights in the molecular interaction of the NNRTIs with the amino acids lining the pocket in HIV-1 RT. Due to their unprecedented specificity, the NNRTIs are relatively non-toxic in cell culture, and the most potent compounds reach selectivity indices that exceed 100,000 or more. However, inherent to their high specificity, the NNRTIs easily select for mutant virus strains with several degrees of drug resistance. The first-generation NNRTIs such as nevirapine and delavirdine easily loose their inhibitory potential against mutant virus strains that contain single amino acid mutations in their RT. The second-generation NNRTIs such as efavirenz, capravirine and dapivirine usually require two or more mutations in the HIV-1 RT before significantly decreasing their antiviral potency. Evidently, it requires a markedly longer time period to obtain significant resistance against second-generation NNRTIs. The resistance spectrum of NNRTIs is entirely different from the NRTI resistance spectrum, and, as a rule, NRTI-resistant mutant virus strains keep full sensitivity to the inhibitory effects of NNRTIs, and vice versa NNRTI-resistant and mutant virus strains keep full sensitivity to the inhibitory effects of NRTIs. NNRTIs have proven beneficial when included in drug combination (triple or quadruple) therapy, preferably in the presence of protease inhibitors and NRTIs.
Export Options
About this article
Cite this article as:
Balzarini J., Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1, Current Topics in Medicinal Chemistry 2004; 4 (9) . https://dx.doi.org/10.2174/1568026043388420
DOI https://dx.doi.org/10.2174/1568026043388420 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer
Current Drug Targets Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Azacitidine Loaded PLGA Nanoparticles and their Dual Release Mechanism
Current Nanomedicine Tumor Stroma Manipulation By MSC
Current Drug Targets Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Current Medicinal Chemistry New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine